Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eli Lilly Japan to Conduct More PI Clinical Trials in Japan
February 16, 2009
- Astellas Has Strongest Image: NPhA Survey
February 16, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 16, 2009
- Council Recommends Health Insurance Coverage for KRAS Gene Mutation Tests
February 16, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 16, 2009
- Astellas Interested in CV Therapeutics' Product Lineup
February 9, 2009
- Mochida to Develop OTC Versions of Epadel
February 9, 2009
- aRigen Licenses New Anti-Peptic Ulcer Agent to Taiho
February 9, 2009
- LDP Diet Members to Discuss Online Sale of OTC Drugs
February 9, 2009
- Novartis to Comarket Lucentis with Alcon Japan
February 9, 2009
- Updated GL for Colon Cancer to Recommend Bevacizumab, Cetuximab
February 9, 2009
- GSK's 1,200 MRs Start Detailing Adoair for COPD
February 9, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 9, 2009
- 3-Qtr Business Results: 1
February 9, 2009
- Korosho to Study Efficacy of Tamiflu against Resistant Strains
February 9, 2009
- BUSINESS NEWS IN BRIEF
February 9, 2009
- SEMINAR
February 9, 2009
- NHI Societies Asked to More Actively Promote Use of Generics
February 9, 2009
- Takeda Obtains Approval for Lansoprazole's Successor in US
February 9, 2009
- Group of Health Insurance Societies to Promote Use of Generics
February 9, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…